
![]() |
Parathyroid hyperplasia is the enlargement of all four parathyroid glands. The parathyroid glands are located in the neck and control the body's break down of calcium. Parathyroid hyperplasia leads to high levels of calcium in the blood (hypercalcemia).
Parathyroid hyperplasia causes about 15% of cases of hyperparathyroidism, which leads to elevated levels of calcium in the blood (hypercalcemia).
Parathyroid hyperplasia may occur sporadically (without a family history) or as part of three familial (inherited) syndromes: multiple endocrine neoplasia 1 (MEN 1) and MEN 2A and isolated familial hyperparathyroidism.
In the familial syndromes, a mutated gene is inherited in an autosomal dominant fashion (you only need to get the gene from one parent to develop the condition).
In MEN 1, the problems in the parathyroids are associated with other tumors in the pituitary and the pancreas. In MEN 2A, the overactivity of the parathyroids is associated with tumors in the adrenal gland or thyroid.
The genetic basis of isolated familial parathyroidism is not yet clear.
Symptoms may include:
The patient may have signs of fractures and renal colic.
Tests may show:
Surgery is the preferred treatment. Usually 3 1/2 glands are removed. The remaining tissue may be implanted in the forearm to regulate calcium levels but allow easy surgical access if hypercalcemia recurs.
The success rate for surgery for parathyroid hyperplasia is lower than that for parathyroid adenoma. Persistent or recurrent hypercalcemia occurs about 20% of the time.
Advanced complications of hyperparathyroidism associated with parathyroid hyperplasia include nephrocalcinosis and osteitis fibrosa cystica.
Patients may also have complications from the other endocrine tumors that are part of the multiple endocrine neoplasia syndromes:
Call your health care provider if you have any symptoms of hypercalcemia, or there is a family history of any of the MEN syndromes
Patients with a family history of the MEN syndromes may be genetically screened for presence of the defective gene and then screened regularly with standard diagnostic methods for endocrine problems if this test is positive.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. � 1997- 2008 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.